<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00300040</url>
  </required_header>
  <id_info>
    <org_study_id>BIOSA001/BIOEU001</org_study_id>
    <nct_id>NCT00300040</nct_id>
  </id_info>
  <brief_title>Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia</brief_title>
  <official_title>Phase II, Multi-Center,Single-Blind,Placebo-Controlled Study,Evaluating Safety &amp; Feasibility of HBOC-201 (Wound Healing Patients With Peripheral Vascular Disease &amp; Undergoing Lower Limb Amputation Due to Critical Lower Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biopure Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biopure Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and feasibility of HBOC-201 in increasing
      adequate wound healing in patients with severe peripheral vascular disease who are undergoing
      lower limb amputation.

      The hypothesis is that HBOC-201 will pass through the partially occluded lesions in the
      peripheral arteries in the lower extremity and promote the wound healing process by
      delivering oxygen to the oxygen deprived tissues. This will reduce the incidence of lower
      limb wound complications at 60 days post-surgery and may reduce the incidence of a second
      amputation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, single-blinded, prospectively randomized, parallel-group, placebo
      controlled study that will evaluate the safety and feasibility of HBOC-201 when administered
      therapeutically to patients with a peripheral vascular occlusive disorder and who are
      undergoing lower limb amputation due to critical lower limb ischemia. Subjects will be
      randomized (1:1) to receive either HBOC-201 or a colloid control (HAES-steril® 6%).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Very slow enrollment.Study entry criteria not in line w/local standards of care
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Anticipated">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality at 60 days post amputation procedure</measure>
    <time_frame>60(±7 days) post-procedure follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>30 day follow up mortality; Complete wound healing 30, 60 day follow up; Time to complete wound healing; Re-amputation 60 days; Hospital, ICU &amp; rehab days; TcPO2 change; Quality of Life; Delayed wound healing/complications; Rehospitalization; Surgeries</measure>
    <time_frame>15(±3 days) , 30(±7 days) and 60(±7 days) post-procedure follow-up visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Peripheral Vascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemoglobin glutamer 250 - bovine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6% Hydroxyethylstarch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hemoglobin glutamer 250 - bovine</intervention_name>
    <description>intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Hemopure</other_name>
    <other_name>HBOC-201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6% Hydroxyethylstarch</intervention_name>
    <description>250ml for intravenous infusion</description>
    <arm_group_label>2</arm_group_label>
    <other_name>HAES-steril®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects ≥ 18 ≤ 75 years of age

          -  Scheduled amputation at or above ankle joint, or a more proximal location but below or
             through the knee joint

          -  Documented severe lower extremity peripheral artery occlusive disease confirmed by
             clinical symptoms of critical limb ischemia and:

               -  Frankly gangrenous tissue that merits amputation or

               -  Angiographic evidence of occlusive peripheral artery disease within one month of
                  screening

          -  Participant or legal representative signs informed consent

          -  Willingness to follow study instructions and follow-up visits

        Exclusion Criteria:

          -  No informed consent is obtained

          -  If medically inappropriate to administer 250 mL colloidal solution daily for 4
             consecutive days

          -  Uncontrolled hypertension (BP &gt; 160/90 mm Hg) despite 2 antihypertensive meds or BP &gt;
             180/100 mm Hg if untreated

          -  Severe liver dysfunction defined by Total Bilirubin &gt; 3 mg/dL or twice the normal
             limit of serum AST or ALT

          -  Symptomatic CVD diagnosed w/ in last 6 months or known high grade carotid stenosis

          -  Any severe or unstable medical condition that might interfere w/ the evaluation of
             study medication

          -  Cardiogenic shock (cardiac index &lt; 2 L/min/m2, PCWP &gt; 18 mm Hg)

          -  Amputation above knee joint or below ankle joint

          -  Any amputation whereby primary skin closure not technically feasible

          -  Candidate for percutaneous or surgical revascularization

          -  Cardiac failure defined by a NY class III/IV or left ventricular ejection fraction &lt;
             30%

          -  Life expectancy &lt; 60 days

          -  Systemic mastocytosis

          -  Previously demonstrated beef product allergy

          -  Myocardial infarction w/ in 30 days

          -  Participation in another trial w/ in last 30 days

          -  Woman who is pregnant or breastfeeding

          -  Amputation with known infection at site of skin closure

          -  Renal dysfunction requiring dialysis, or serum creatinine level 2.5 mg/dL

          -  Peripheral vascular occlusion from cardio arterial emboli

          -  Uncontrolled diabetes blood glucose ≥ 400 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Gerson Greenburg, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biopure Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johannesburg Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Guateng</state>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Milpark Hospital</name>
      <address>
        <city>Parktown West</city>
        <state>Guateng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pretoria Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Guateng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Stellenbosch</name>
      <address>
        <city>Tygerburg</city>
        <zip>7506</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Headington</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2006</study_first_posted>
  <last_update_submitted>May 15, 2008</last_update_submitted>
  <last_update_submitted_qc>May 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Biopure</name_title>
    <organization>Biopure</organization>
  </responsible_party>
  <keyword>Amputation</keyword>
  <keyword>Lower limb</keyword>
  <keyword>Critical Limb Ischemia</keyword>
  <keyword>residual limb</keyword>
  <keyword>Peripheral Vascular Disease</keyword>
  <keyword>re-amputation</keyword>
  <keyword>Lower Limb Ischemia</keyword>
  <keyword>PVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
    <mesh_term>HBOC 201</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

